PMVP

PMV Pharmaceuticals, Inc.

Phase 2 Confirmed

rezatapopt

platinum-resistant/refractory ovarian cancer

Resolved

86days ago

Phase 2 readout · Apr 12, 2026

What's at stake Phase 2 trial results for rezatapopt in platinum-resistant/refractory ovarian cancer are due Apr 12, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 16h ago

“Post the March 29, 2026 data cutoff, two additional patients achieved unconfirmed partial responses (uPRs), bringing the ORR to 46% (34/74).”

Add to calendar Post on X Reddit

Provenance